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Background: Chromosome 22q11.2 deletion syndrome (22q11DS) is the most common human microdeletion
syndrome and is associated with many cognitive, neurological and psychiatric disorders. The majority of individuals
have a 3 Mb deletion while others have a nested 1.5 Mb deletion, but rare atypical deletions have also been
described. To date, a study using droplet digital PCR (ddPCR) has not been conducted to systematically map the
chromosomal breakpoints in individuals with 22q11DS, which would provide important genotypic insight into the
various phenotypes observed in this syndrome.
Methods: This study uses ddPCR to assess copy number (CN) changes within the chromosome 22q11 deletion
region and allows the mapping of the deletion endpoints. We used eight TaqMan assays interspersed throughout
the deleted region of 22q11.2 to characterize the deleted region of chromosome 22 in 80 individuals known to
have 22q11DS by FISH. Ten EvaGreen assays were used for finer mapping of the six identified individuals with
22q11DS atypical deletions and covering different regions of chromosome 22.
Results: ddPCR provided non-ambiguous CN measurements across the region, confirmed the presence of the
deletion in the individuals screened, and led to the identification of five differently sized and located deletions.
The majority of the participants (n = 74) had the large 3 Mb deletions, whereas three had the smaller 1.5 Mb
deletions, and the remaining three had an interstitial deletion of different size.
Conclusions: The lower cost, rapid execution and high reliability and specificity provided by ddPCR for CN
measurements in the 22q11 region constitutes a significant improvement over the variable CN values generated by
other technologies. The ability of the ddPCR approach, to provide a high resolution mapping of deletion endpoints
may result in the identification of genes that are haplo-insufficient and play a role in the pathogenesis of 22q11DS.
Finally, this methodology can be applied to the characterization of other microdeletions throughout the genome.
Keywords: Droplet digital PCR, 22q11DS, qPCR, copy number, LCRBackground
Chromosome 22q11.2 Deletion Syndrome (22q11DS) is the
most frequent microdeletion syndrome in humans with an
estimated prevalence of 1:3000–1:6000 live births [1-4]. A
wide array of phenotypes has been associated with this
syndrome including structural malformations (congenital* Correspondence: ftassone@ucdavis.edu
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unless otherwise stated.heart disease (CHD), thyroid abnormalities, and hypocal-
cemia) and neurodevelopmental and neurological deficits
(Intellectual Disabilities (ID), Attention Deficit Hyper-
activity Disorder (ADHD) and seizures) [5].
The majority of 22q11 deletions arise de novo (90%)
and only a small minority (10%) is inherited. The high
frequency of de novo events has been attributed to the
high mutation-rearrangement rate associated with sev-
eral low copy repeat (LCR) regions throughout the 22q
deletion region [6,7]. The LCRs found in 22q are larger
and have higher sequence similarity than most other
LCR regions in the genome, possibly explaining theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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compared to other chromosomal deletion syndromes
[8,9]. It is thought that the majority of individuals with
22q11DS have deletion breakpoints located within the
22q11 LCRs. Indeed, 70-80% of these individuals have
the 3 Mb deletion (between LCR A and D), 10-15% have
a nested 1.5 Mb deletion (between LCR A and B), and
the remaining have atypical deletions [7,10-33]. These
deletions are likely the results of unequal crossing-over
during meiosis involving smaller LCRs within the de-
leted regions.
Multiple studies have attempted to delineate the dele-
tion endpoints in individuals with 22q11DS; however,
the difficulty in designing unique primers or identifying
unique SNPs in the proximity or within these repeat re-
gions has hindered the progress of locating the exact
position of the deletion endpoints which remains poorly
defined [10,34-36].
Several studies have also attempted to elucidate
genotype-phenotype correlations among individuals with
22q11DS or to identify a minimal region of disease, but
these correlations are still not well understood [12,15].
Reports of individuals with different size deletions that
cover nearby, non-overlapping regions and presenting
with similar clinical phenotypes stress the importance of
delineating the exact deletion endpoints in order to
accurately bin individuals and specific phenotypes. Spe-
cifically, Amati et al. [14] and Yamagishi et al. [20] de-
scribed several cases with different, adjacent deletions
located between LCR-A and LCR-B that presented with
CHD and facial dysmorphism. These observations sug-
gest that a minimal critical region for these phenotypes
that exists between LCR-A and LCR-B. The need for
better genotype and phenotype correlations in individ-
uals with 22q11DS makes it important to screen a large
cohort with high resolution in order to determine the
exact deletion breakpoints and to correctly identify those
regions that may correlate to specific phenotypes.
So far, the methodologies utilized for gene copy num-
ber quantification have often given inconsistent results
in target populations. Currently, the gold standard
method of diagnosis for 22q11DS is by fluorescent in-
situ hybridization (FISH) [5,37]. However, this approach
is labor intensive, expensive, requires specialized and
well trained technicians and equipment, and may not
identify a small portion of individuals with 22q11DS. In
addition, it is difficult to adopt FISH in a high throughput
setting. Other methodologies currently used to determine
the presence of a deletion and to delineate the endpoints
for 22q11DS include: multiplex ligation-dependent probe
amplification (MLPA) [38], quantitative PCR (qPCR) [35],
and multiple types of chromosomal arrays (single nucleo-
tide polymorphisms microarrays, (SNPs) and array-based
comparative genomic hybridization, aCGH) [39]. However,none of these have been shown to be high-throughput, ro-
bust and cost-effective. Specifically, the high cost and tech-
nical complexity of the CGH array make it unsuitable for
routine diagnostic use and for high throughput testing.
Various steps have been found to be critical and limiting
for the performance of MLPA including the choice of the
reference DNA, incomplete denaturation, and sensitivity to
DNA and salt concentration [40,41]. Lastly, qPCR is prone
to false positive results, perhaps due to the limited effi-
ciency of the oligonucleotide probes, nucleotide content of
the target region and susceptibility to inhibitors [42,43].
Droplet digital PCR (ddPCR) is a new approach to
nucleic acid detection and quantification and gives ex-
tremely robust values as samples are partitioned into
approximately 20,000 water-in-oil droplets, allowing
many thousands of discrete measurements to be made.
Additionally, as the partitioning of a DNA sample
allows for an independent reaction in each droplet,
robust CN measurements with 95% confidence can be
generated. The binary nature of ddPCR makes it toler-
ant to differences in PCR amplification efficiency, often
allowing for no overlap of 95% confidence intervals for
adjacent copy number states [44] and has been demon-
strated to possess a high level of accuracy and preci-
sion for determining copy number quantification [45].
Finally, as multiplexing can be easily performed using
ddPCR, the ~4$ cost per sample allows not only the
detection of 22q11DS but simultaneously allows the
differentiation between the two common deletions
(3 Mb and 1.5 Mb).
In this study, we utilized ddPCR for CN value mea-
surements at different locations within the 22q11.2
region to finely map the deletion breakpoints in 80 indi-
viduals with 22q11DS. We demonstrate that ddPCR is a
precise and reliable approach for detecting CN variation
within the 22q11 locus (using either Taqman or EvaGreen
assays) and that ddPCR can be used to delineate the
deletion endpoints, which may be helpful in identifying
the critical regions corresponding to disease. We also
used ddPCR to study genotype-phenotype correlations
in 22q11DS and to examine its application for diagnos-
tic and clinical purposes.
Methods
Human participants
Participants were recruited at the UC Davis Medical In-
vestigation of Neurodevelopmental Disorders (MIND)
Institute located in Sacramento, under written consent
from the next of kin, caretakers, or guardians on the be-
half of the minors/children participants and according to
a UC Davis Institutional Review Board (IRB) approved
protocol. The diagnosis of 22q11DS was obtained for the
participants by FISH analysis using the TUPLE1 probe.
No information on the size and the position of the
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study using ddPCR was conducted in order to deter-
mine the deletion status of participants with 22q11DS.
95 participants, including 80 individuals (48 males and
32 females) with 22q11DS and 15 TD controls (8 males
and 7 females) were chosen. Age range was 7–15 for
22q11DS and 8–14 for TD. Demographic and clinical
diagnoses are shown in Table 1.
Clinical measures
All participants with 22q11DS were examined by a de-
velopmental behavioral pediatrician (DBP) or child and
adolescent psychiatrist and also underwent neuro-
psychological assessment, including FSIQ using the
WISC-4 [46]. FSIQ ≤70 (2 standard deviations below
normed means) was used to define abnormally low
FSIQ in line with accepted classifications for mental
retardation/intellectual disability. Presence of physical
conditions (neurologic, cardiac, endocrine, etc.) was
obtained from medical history from the parents during
the visit with the DBP or psychiatrist, including current
and past medications, and when available, medical record
abstraction. Examples of abnormal medical conditions
included seizures and congenital heart disease such as
Tetralogy of Fallot, Truncus Arteriousus, and septal de-
fects. Endocrine disturbances such as hypocalcemia and
hyper/hypothyroidism were also documented. Participants
were considered to have ADHD if scores on the parent-
completed SNAP-IV [47] were above the 95% cutoff
for ADHD-inattentive, ADHD-hyperactive, or ADHD-
combined type. All TD participants had FSIQ > 85 on the
WASI [48].
DNA isolation
Genomic DNA (gDNA) from 80 individuals with
22q11DS and 15 TD individuals was isolated from
3–5 mL of peripheral blood leukocytes using standard
procedure (Qiagen, Valencia, CA).
ddPCR
ddPCR involves partitioning the PCR reaction mix into
uniform-size droplets, thermal cycling to end-point fluores-
cence and then singulating and reading the fluorescence of
each droplet. Using an assay specific to amplify the DNA
targets of interest will result in a fluorescent signal derived
from the droplets that contain the DNA target while no sig-
nal will be detected from those that do not contain target
DNA. Thus, each droplet is counted and able to report an
actual number of copies in the sample. For the TaqMan re-
actions, 2 μg of gDNA was digested at 37°C for 1 hour, with
MseI in NEB Buffer 2.1, in a final volume of 10 μL. An
assay mix containing 100 ng of digested gDNA, Droplet
PCR supermix (BioRad Laboratories, Hercules, CA), and
gene assay at a final concentration of 900 nM per primerand 250 nM probe in a 25 μL final volume was prepared.
For the EvaGreen reactions, an assay mix containing
100 ng of gDNA, 5 units MseI, QX200 ddPCR EvaGreen
supermix (BioRad Laboratories, Hercules, CA), and gene
assay at a final concentration of 100 nM per primer in a
25 μL final volume was prepared. 20 μL of assay mix and
70 μL of ddPCR droplet oil (BioRad Laboratories, Hercules,
CA) were transferred onto a QX100/200 DG cartridge
(BioRad Laboratories, Hercules, CA), then loaded into the
QX100 Droplet Generator (BioRad Laboratories, Hercules,
CA). Vacuum was applied, pulling individual samples and
oil through a flow-focusing junction to produce ~20,000
water-in-oil droplets. 40 μL of the oil and sample droplet
emulsions were then transferred into a 96 well plate and
thermocycled in a standard themocycler (BioRad Labora-
tories, Hercules, CA) for 95°C for 10 minutes, 94°C for
1 min and 59°C for 1 min (repeated 40 times) and 98°C for
10 minutes (TaqMan reactions) or 95°C for 5 minutes,
96°C for 30 seconds and 60°C for 1 minute (repeated 40
times), 4°C for 5 minutes and 90°C for 5 minutes (EvaGreen
reactions). The plate was then transferred to a QX200
Droplet Reader (BioRad Laboratories, Hercules, CA) and
analyzed by QuantaSoft (BioRad Laboratories, Hercules,
CA). For the TaqMan assays, the presence of 2 copies of
any given gene region was scored by a CNV value of 2 ± 0.1
and a hemizygous deletion (1 copy) of a region was scored
by a CNV value of 1 ± 0.1. For the EvaGreen assays, a hemi-
zygous deletion of a region was scored by a CNV value of
1 ± 0.4. TaqMan target primers were designed as described
by Weksberg et al. [35]. D22S181, PRODH, and D22S936
were specifically chosen to help elucidate the position of
the deletion breakpoints. RPP30, a reference assay com-
monly used in ddPCR CNV studies, as it is located in a
conserved region on the genome not known to undergo
copy number variation, was used as the control [44]. The
control probe (RPP30) was labeled with VIC and all target
probes were labeled with FAM unless otherwise described.
TaqMan and EvaGreen primer sequences were as shown in
Tables 2 and 3.
To calculate CN measurements for the TaqMan assays,
automatic thresholding in Quantasoft was performed on
the 2D fluorescent amplitude plot (Figure 1). CN was cal-
culated as (a/b)*c where “a” is the copy of DNA target
gene (assays 1–8) per microliter, “b” is the copy of the ref-
erence gene (RPP30) per microliter and “c” is the CN of
the reference gene per genome. Average CN values for all
assays are reported in Table 4. To calculate CN measure-
ments for the Evagreen assays, CN was calculated as (d/e)
*2 where “d” is the concentration of the target assay and
“e” is the concentration of the reference assay (Table 5).
Quantitative PCR
Genomic DNA (gDNA) in a subgroup of 40 participants
with 22q11DS was analyzed by qPCR using the methods
Table 1 Demographic information and clinical diagnoses
Dx No subjects Gender Age range Deletion Severity Phenotypes





22q 80 M = 48 F = 32 M = 7-15 F = 8-15
PRODH-D22S936 3 Mb deletion
Normal 45 (58%) 47 (59%) 59 (75%) 38 (47%) 50 (64%) 62 (78%)
Abnormal 27 (35%) 26 (33%) 14 (18%) 36 (45%) 22 (28%) 11 (14%)
PRODH-DGCR6L 1.5 Mb deletion
Normal 1 (1.3%) 0 2 (2.5%) 2 (2.5%) 3 (4%) 3 (4%)
Abnormal 2 (3%) 3 (4%) 1 (1.3%) 1 (1.3%) 0 0
TUPLE1-SHGC-2421 Atypical deletion
Normal 1 (1.3%) 0 0 0 0 1 (1.3%)
Abnormal 0 1 (1.3%) 1 (1.3%) 1 (1.3%) 1 (1.3%) 0
TUPLE1-D22S936 Atypical deletion
Normal 1 (1.3%) 1 (1.3%) 1 (1.3%) 1 (1.3%) 1 (1.3%) 1 (1.3%)
Abnormal 0 0 0 0 0 0
ZNF74-D22S936 Atypical deletion
Normal 0 1 (1.3%) 1 (1.3%) 1 (1.3%) 1 (1.3%) 1 (1.3%)
Abnormal 1 (1.3%) 0 0 0 0 0
TD 15 M = 8 F = 7 M = 8-14 F = 9-13 N/A N/A N/A N/A N/A N/A N/A N/A N/A





















Table 3 EvaGreen primer sequences









































Table 2 TaqMan primer sequences
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tions. Target assays used from Weksberg et al. [35] were
the same as those used for ddPCR and reference assays
used were HEM3 and G6PDH (2005). For each sample,
quantitative-PCR reactions were performed in two inde-
pendent runs in duplicates. Control reactions were run
in parallel. Reactions were performed using FastStart
Universal SYBR Green Master Mix (Roche, Applied Sci-
ence, Indianapolis, IN) (which includes the internal ref-
erence (ROX), forward and reverse primers at final
concentrations of 800 nM for the target primers and 400
nM for the reference primers, and 10 ng of genomic
DNA. The qPCR reactions were run using the Applied
Biosystems 7900HT FAST real-time PCR system (Foster
City, CA) with 2 min at 50°C, 10 min at 95°C followed
by 40 cycles of 15 sec at 95°C and 60 sec at 60°C.
Statistical analysis
QuantaSoft software (version 1.3.2) (Bio-Rad Laborator-
ies, Hercules, CA) was used to analyze the ddPCR data
and to calculate the copy number estimations. qPCR
data was analyzed using the comparative Ct method
after data normalization [35].
Results and discussion
Deletion endpoints
To characterize the size and the location of deletions of
80 individuals known to have 22q11DS by FISH, we used
ddPCR to define their deletion endpoints. In this study,
15 typically developing (TD) individuals were used as
controls in this study. Our analysis involved 8 loci span-
ning an approximately 4 Mb region of chromosome
22q11.2. The two outermost genes are thought to be un-
altered in individuals with 22q11DS (D22S181 and
VPREB1). In all cases, 2 copies of chromosome 22 weredetected in the TD (Figure 2A) and either the 3 Mb
(Figure 2B) or 1.5 Mb (Figure 2C) deletions were identi-
fied in the individuals with 22q11DS with no ambiguity.
We found that 74 individuals carried the 3 Mb deletion
and had 1 copy of the 6 genes located within the deleted
region and 2 copies of the 2 genes located outside
(D22S181 and VPREB1; Figure 2B,C and Figure 3). The
remaining 6 individuals with 22q11DS, 3 with the
1.5 Mb deletion and 3 with an interstitial (non-contigu-
ous interspersed deletions) deletion presented with 1
copy of those genes located within the specific deleted
region (Figure 2C, and Figure 3). Finally, 15 typically de-
veloping (TD) control individuals showed the presence
of 2 copies of the 8 genes tested except for one individ-
ual who showed a duplication of the PRODH gene. The
types of deletion found in the individuals in our study
samples represent the expected distribution in the
22q11DS population, as we found 92% of individuals
having the 3 Mb deletion, 4% having the 1.5 Mb dele-
tion, and 4% having atypical deletions. The majority of
individuals had deletions encompassing PRODH and
D22S936 with deletion breakpoints near or within LCR-
A and LCR-D. None of the 80 samples had a distal dele-
tion extending beyond the LCR-A and LCR-D region,
supporting the hypothesis that the majority of 22q11DS
individuals have deletion breakpoints located near or
within those regions.
Interestingly, three individuals carried interstitial dele-
tions of different sizes and locations, likely originating
from more rare events involving smaller LCRs present
throughout the 22q deleted region. To perform higher
Figure 1 2D Fluorescent Amplitude Plot. Cluster (A) comprises the double negative droplets (droplets containing no amplicons). Cluster (B)
contains droplets containing the reference amplicon. Cluster (C) contains droplets containing the target amplicon. Cluster (D) comprises the
double positive droplets (droplets containing both target and reference amplicons).
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tion breakpoints, we used ten additional EvaGreen as-
says to clarify the deletion region for the six individuals
with the less common deletions (Figure 3). Specifically,
the three individuals with the 1.5 Mb deletion showed a
deletion between PRODH and DGCR6L, and the three
individuals with the atypical deletions showed a deletion
between TUPLE1 and SHGC-2421, ZNF74 and D22S936,
or TUPLE1 and D22S936 (Figure 3). Average copy num-
ber values are reported in Tables 4 and 5.Table 4 Copy number values for TaqMan-based ddPCR
assays
Assay TD 22q11DS*
Average Std Err Average Std Err
D22S181 2.04 0.03 2.02 0.05
PRODH 2.09 0.08 1.03 0.12
TUPLE1 2.03 0.04 1.02 0.12
COMT 2.06 0.07 1.02 0.12
ZNF74 1.96 0.04 0.97 0.16
PIK4CA 2.03 0.03 1.03 0.12
D22S936 2.05 0.07 1.02 0.12
VPREB1 2.04 0.08 2.08 0.44
Average 2.04 0.09 1.02 0.13
*22q11DS values are only shown for individuals with the 3 Mb deletion
spanning the region from PRODH-D22S936.Comparison between qPCR and ddPCR
To determine whether ddPCR offers advantages, particu-
larly in performance, reliability and specificity, over
qPCR for 22q11DS detection, we analyzed a subgroup of
40 individuals with 22q11DS by qPCR (SYBR Green)
using the same eight assays used for ddPCR (Taqman)
analysis. qPCR data showed that 18 (53%) of these indi-
viduals had non-contiguous interstitial deletions, which
were determined to be contiguous by ddPCR. Of the in-
dividuals tested, 2 (6%) were determined to have a larger
deletion than that resolved by ddPCR and 4 (12%) were
determined to have smaller deletions than that resolved
by ddPCR. Only 6 (15%) of the qPCR deletion endpoint
determinations were the same as those obtained with
ddPCR (Figure 4). In respect to the copy number in the
TUPLE1 gene (for comparison with FISH data), ddPCR
results for 80 individuals with 22q11DS and 15 TD indi-
viduals was found to be 100% specific (Table 6), whereas
qPCR results for 19 individuals with 22q11DS and 11
TD individuals was only 58.6% specific (Table 7). Thus,in our hands, qPCR failed to accurately define the dele-
tion breakpoints, possibly due to its reliance on standard
curves and its sensitivity to amplification efficiencies and
thus, it may not provide sufficient accuracy to serve as a
comprehensive diagnostic tool.
Advantages of TaqMan-based ddPCR include no need
for a standard curve, multiple targets and reference gene
are measured in the same well and greater tolerance to
differences in amplification efficiencies, which together
result in much more robust CN measurements. Further-
more, our data indicates the assays used in this study
have a specificity of 100% (95% Confidence Interval =
95.5-100%), allowing us to delineate deletion sizes and
locations with great certainty, making it a preferred tool
for diagnostics.
Table 5 Copy number values for EvaGreen-based ddPCR
assays
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The ddPCR data on the deletion endpoints was used to
investigate whether the deletion type/size correlated with
various clinical phenotypes including IQ, ADHD, seizures,
CHD, hypocalcemia, and thyroid abnormalities (as listed
in Table 1) to potentially narrow down a minimal region
for disease in the subjects included in this study. TheFigure 2 Diagram of CNV values by QuantaSoft. CNV values for A) a TD in
a nested 1.5 Mb deletion are represented by each of the 8 TaqMan assays nomajority of individuals in our 22q11DS cohort (~62%) had
higher (>70) than average IQ scores with a mean score of
73 (±13), while ADHD was diagnosed in 38% of them.
Thyroid abnormalities, seizures and CHD were seen in
14%, 21% and 38% of the participants, respectively. Exam-
ination of the clinical phenotypes present in all individuals
indicated that many of the clinical features were present
in those with the 1.5 Mb deletion defined between locus
PRODH and ZNF74 (LCR-A and LCR-B). Interestingly,
one of the individuals with an atypical deletion mapping
approximately between locus ZNF74 and D22S936 (LCR-
B and LCR-D), had ID while another individual with an
atypical deletion mapping approximately between locus
TUPLE1 and SHGC-2421 presented with ADHD, seizures,
CHD and hypocalcemia and another individual with an
atypical deletion mapping between locus PRODH and
DGCR6L presented with seizures and CHD. In addition,
the three individuals with the nested deletion (1.5 Mb)
had ID and ADHD and one had a more severe phenotype
including CHD and seizures. This indicates that other fac-
tors (in addition to the 22q11 deletion) are playing a role
in the broad variation of the observed phenotype. How-
ever, this region of chromosome 22 contains many genes
including HIRA, TBX1, and DGCR8, all of which aredividual B) an individual with a 3 Mb deletion and C) an individual with
ted at the bottom. 95% Confidence Interval are shown for each sample.
Figure 3 Sizes and types of chromosome 22 deletions. The diagram summarizes the deletions identified in the 80 participants of the study.
Diamond regions indicate a hemizygous deletion of one gene copy; solid dark regions indicate the presence of two copies of chromosome 22;
solid light regions indicate uncertain areas of deletion. Locations of assays in base pairs are noted (as reported in the UCSC Genome Browser,
2013). Numbers of individuals are noted on the left. Genes in black indicate TaqMan assays and genes in red indicate EvaGreen assays.
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is thought to be the key player for CHD, the presence of
individuals with 22q11DS with CHD but without a TBX1
deletion and the lack of pathogenic mutations identified in
the gene suggest that deletion of TBX1 alone, is not suffi-
cient to give rise to CHD [17,49-51]. Our findings confirm
previous reports [32,39] indicating that the correlation be-
tween the size or/and position of the deleted region and
the broad spectrum of phenotypes is not straightforward
and that other factors play a role in contributing to the
phenotypes observed in 22q11DS.
One of the genes mapping to the deleted region of
chromosome 22q11.2 is DGCR8, a gene expected to affect
multiple genes as it plays an important role in microRNA
(miRNA) biogenesis. miRNAs are small non-coding RNA
molecules that are initially transcribed by RNA Polymerase
II as primary miRNAs transcripts; then processed intoprecursor miRNAs by DROSHA and DGCR8 (which an-
chors DROSHA to the primary miRNA) [52-56]. Precursor
miRNAs are then exported into the cytoplasm where they
are processed into mature miRNAs by the DICER enzyme
[57-59]. miRNAs are post-transcriptional gene expression
regulators, and can inhibit mRNA translation or promote
mRNA degradation [57]. Therefore, hemizygous deletion
of DGCR8 could alter the expression of multiple genes.
Several studies in mice and humans have demonstrated a
possible correlation of miRNA dysregulation with CHD
phenotype in 22q11DS [60-62].
Finally, building genotype-phenotype correlations
in 22q11DS can allow for better interventions in indi-
viduals with 22q11DS. Similarly, they also function
to provide an understanding of the role of the genes
in these deleted regions in disorders like ADHD and
schizophrenia.
Figure 4 qPCR (SYBR Green) vs. ddPCR (TaqMan) results. Graphic representation of qPCR results for five representative cases for
A) individuals with 22q11DS and B) TD individuals across all 8 assays used in ddPCR (TaqMan). The first individual for each graph represents
one where qPCR and ddPCR results were concordant. The y-axis indicates the copy number and the x-axis indicates the position of the 8
assays used in the analysis.
Table 6 Specificity of diagnosis calls by TaqMan-based
ddPCR
Outcome ddPCR assay Positive Negative Total
Positive 80 0 80
Negative 0 15 15
Total 80 15 95
Results obtained by TaqMan-based ddPCR are compared to the diagnosis of
22q11DS obtained by FISH using the TUPLE1 gene Specificity was 100% as all
80 individuals were correctly identified as having 1 copy of the TUPLE1 gene.
Table 7 Specificity of diagnosis calls by qPCR
Outcome qPCR assay Positive Negative Total
Positive 17 0 17
Negative 12 11 23
Total 29 11 40
Results obtained by qPCR are compared to the diagnosis of 22q11DS obtained
by FISH using the TUPLE1 gene. Specificity of diagnosis calls for qPCR was
58.6% as ddPCR results, conducted in a subgroup of 40 individuals (29 with
22q11DS and 11 TD) correctly identified 1 copy of the TUPLE1 gene only in 17
individuals with 22q11DS.
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In this study we demonstrate the feasibility of ddPCR for
detecting and mapping deletions of chromosome 22q11.2.
While other methods have been used to elucidate deletion
endpoints in individuals with 22q11DS, none have all the
qualities required for an effective and reliable diagnostic
tool. Additionally, clinical and molecular diagnostics re-
quire methodologies that are robust, cost effective and at
high throughput.
Although it is not common medical practice to iden-
tify the extent of patients’ deletions or the location, it
may be important, in some cases, to better characterize
the LCRs and individual’s deletion, size and location.
However, many of the genes involved in clinical pheno-
types in 22q11DS appear to be located in the common
1.5 Mb deletion region between LCR A-B.
Our findings support the hypothesis that the majority
of individuals with 22q11DS have deletion breakpoints
located near or within LCRs A and D. Two individuals
appear to have breakpoints localized within smaller
LCRs scattered along chromosome 22.
Importantly, in this study we show that ddPCR is an
ideal technology for detecting 22q11DS and can allow
fine mapping of the deleted region using either TaqMan
or EvaGreen assays and may be qualified for use in a
clinical setting. ddPCR is a high throughput, cost effect-
ive technology that allows absolute measure of nucleic
acid concentration, providing highly accurate estima-
tions of DNA copy number. Approximately 200 samples
can be easily run and analyzed daily, without the difficul-
ties, ambiguity, time and cost of other methodologies,
making ddPCR the preferred tool for determining DNA
copy number variation in large population screening
studies.Abbreviations
22q11DS: 22q11.2 Deletion Syndrome; ddPCR: droplet digital PCR; CN:
Copy Number; CHD: Congenital Heart Disease; ID: Intellectual Disabilities;
ADHD: Attention Deficit Hyperactivity Disorder; LCR: Low Copy Repeats;
FISH: Fluorescent In-Situ Hybridization; MLPA: Multiplex Ligation-Dependent
Probe Amplification; qPCR: quantitative PCR; aCHG: array comparative
genomic hybridization; TD: Typically Developing Controls; miRNA: microRNA.Competing interests
Dr. Tassone has received funds from Roche. Dr. Angkustsiri is involved in
clinical trials through Roche, Novartis, Seaside, Forest, and SynapDx.Authors’ contributions
VH performed the experiments and participated to the analysis and writing
of the manuscript. DM performed the experiments, performed analysis and
participated to the writing of the manuscript. JR performed analysis and
participated to the writing of the manuscript. KA performed clinical
evaluations of the participants in the study and participated in the writing of
the manuscript. TS recruited individuals in the study and participated to the
writing of the manuscript. FT conceived the study, its design, coordination
and analysis and participated to the writing of the manuscript. All authors
read and approved the final manuscript.Acknowledgements
The study was supported by the NIH R01HD042974 grant and by Gift funds.
We want to thank Nimrah Choudhary for technical help. This work is
dedicated to the memory of Matteo.
Author details
1Department of Biochemistry and Molecular Medicine, UC Davis, 2700
Stockton Blvd, Suite 2102, Sacramento, CA 95817, USA. 2Digital Biology
Center, Bio-Rad Laboratories, 5731 West Las Positas Blvd, Pleasanton, CA
94588 USA. 3MIND Institute, UC Davis Medical Center, Wet Lab Room 2418,
2805 50th Street, Sacramento, CA 95817, USA. 4Department of Pediatrics, UC
Davis Medical Center, Sacramento, CA, USA. 5Department of Psychiatry, UC
Davis Medical Center, Sacramento, CA, USA.
Received: 7 June 2014 Accepted: 9 September 2014References
1. Botto LD, May K, Fernhoff PM, Correa A, Coleman K, Rasmussen SA,
Merritt RK, O’Leary LA, Wong LY, Elixson EM, Mahle WT, Campbell RM:
A population-based study of the 22q11.2 deletion: phenotype, incidence,
and contribution to major birth defects in the population. Pediatrics 2003,
112(1 Pt 1):101–107.
2. Goodship J, Cross I, LiLing J, Wren C: A population study of chromosome
22q11 deletions in infancy. Arch Dis Child 1998, 79(4):348–351.
3. Tezenas Du Montcel S, Mendizabai H, Ayme S, Levy A, Philip N: Prevalence of
22q11 microdeletion. J Med Genet 1996, 33(8):719.
4. Wilson DI, Burn J, Scambler P, Goodship J: DiGeorge syndrome: part of
CATCH 22. J Med Genet 1993, 30(10):852–856.
5. McDonald-McGinn DM, Sullivan KE: Chromosome 22q11.2 deletion
syndrome (DiGeorge syndrome/velocardiofacial syndrome). Medicine
2011, 90(1):1–18.
6. Edelmann L, Pandita RK, Spiteri E, Funke B, Goldberg R, Palanisamy N,
Chaganti RS, Magenis E, Shprintzen RJ, Morrow BE: A common molecular
basis for rearrangement disorders on chromosome 22q11. Hum Mol
Genet 1999, 8(7):1157–1167.
7. Shaikh TH, Kurahashi H, Emanuel BS: Evolutionarily conserved low copy
repeats (LCRs) in 22q11 mediate deletions, duplications, translocations,
and genomic instability: an update and literature review. Genet Med: Off J
Am College Med Genet 2001, 3(1):6–13.
8. Oskarsdottir S: Incidence and prevalence of the 22q11 deletion
syndrome: a population-based study in Western Sweden. Arch Dis Child
2004, 89(2):148–151.
9. Kobrynski LJ, Sullivan KE: Velocardiofacial syndrome, DiGeorge syndrome:
the chromosome 22q11.2 deletion syndromes. Lancet 2007, 370
(9596):1443–1452.
10. Carlson C, Sirotkin H, Pandita R, Goldberg R, McKie J, Wadey R, Patanjali SR,
Weissman SM, Anyane-Yeboa K, Warburton D, Scambler P, Shprintzen R,
Kucherlapati R, Morrow BE: Molecular definition of 22q11 deletions in 151
velo-cardio-facial syndrome patients. Am J Hum Genet 1997, 61(3):620–629.
11. Garcia-Minaur S, Fantes J, Murray RS, Porteous ME, Strain L, Burns JE,
Stephen J, Warner JP: A novel atypical 22q11.2 distal deletion in father
and son. J Med Genet 2002, 39(10):E62.
12. Rauch A, Zink S, Zweier C, Thiel CT, Koch A, Rauch R, Lascorz J, Huffmeier U,
Weyand M, Singer H, Hofbeck M: Systematic assessment of atypical
deletions reveals genotype-phenotype correlation in 22q11.2. J Med
Genet 2005, 42(11):871–876.
13. Rauch A, Pfeiffer RA, Leipold G, Singer H, Tigges M, Hofbeck M: A novel
22q11.2 microdeletion in DiGeorge syndrome. Am J Hum Genet 1999,
64(2):659–666.
14. Amati F, Conti E, Novelli A, Bengala M, Diglio MC, Marino B, Giannotti A,
Gabrielli O, Novelli G, Dallapiccola B: Atypical deletions suggest five
22q11.2 critical regions related to the DiGeorge/velo-cardio-facial
syndrome. Eur J Hum Genet 1999, 7(8):903–909.
15. Kurahashi H, Tsuda E, Kohama R, Nakayama T, Masuno M, Imaizumi K,
Kamiya T, Sano T, Okada S, Nishisho I: Another critical region for deletion
of 22q11: a study of 100 patients. Am J Med Genet 1997, 72(2):180–185.
16. Wieser R, Fritz B, Ullmann R, Muller I, Galhuber M, Storlazzi CT, Ramaswamy
A, Christiansen H, Shimizu N, Rehder H: Novel rearrangement of
chromosome band 22q11.2 causing 22q11 microdeletion syndrome-like
Hwang et al. BMC Medical Genetics 2014, 15:106 Page 11 of 12
http://www.biomedcentral.com/1471-2350/15/106phenotype and rhabdoid tumor of the kidney. Hum Mutat 2005,
26(2):78–83.
17. O’Donnell H, McKeown C, Gould C, Morrow B, Scambler P: Detection of an
atypical 22q11 deletion that has no overlap with the DiGeorge
syndrome critical region. Am J Hum Genet 1997, 60(6):1544–1548.
18. Saitta SC, McGrath JM, Mensch H, Shaikh TH, Zackai EH, Emanuel BS:
A 22q11.2 deletion that excludes UFD1L and CDC45L in a patient
with conotruncal and craniofacial defects. Am J Hum Genet 1999,
65(2):562–566.
19. Lu JH, Chung MY, Betau H, Chien HP, Lu JK: Molecular characterization of
tetralogy of fallot within Digeorge critical region of the chromosome 22.
Pediatr Cardiol 2001, 22(4):279–284.
20. Yamagishi H, Garg V, Matsuoka R, Thomas T, Srivastava D: A molecular
pathway revealing a genetic basis for human cardiac and craniofacial
defects. Science 1999, 283(5405):1158–1161.
21. Kurahashi H, Nakayama T, Osugi Y, Tsuda E, Masuno M, Imaizumi K, Kamiya
T, Sano T, Okada S, Nishisho I: Deletion mapping of 22q11 in CATCH22
syndrome: identification of a second critical region. Am J Hum Genet
1996, 58(6):1377–1381.
22. Verhoeven W, Egger J, Brunner H, de Leeuw N: A patient with a de novo
distal 22q11.2 microdeletion and anxiety disorder. Am J Med Genet 2011,
155A(2):392–397.
23. Ben-Shachar S, Ou Z, Shaw CA, Belmont JW, Patel MS, Hummel M, Amato S,
Tartaglia N, Berg J, Sutton VR, Lalani SR, Chinault AC, Cheung SW, Lupski JR,
Patel A: 22q11.2 distal deletion: a recurrent genomic disorder distinct
from DiGeorge syndrome and velocardiofacial syndrome. Am J Hum
Genet 2008, 82(1):214–221.
24. McQuade L, Christodoulou J, Budarf M, Sachdev R, Wilson M, Emanuel B,
Colley A: Patient with a 22q11.2 deletion with no overlap of the minimal
DiGeorge syndrome critical region (MDGCR). Am J Med Genet 1999,
86(1):27–33.
25. Rodningen OK, Prescott T, Eriksson AS, Rosby O: 1.4Mb recurrent 22q11.2
distal deletion syndrome, two new cases expand the phenotype. Eur J
Med Genet 2008, 51(6):646–650.
26. Newbern J, Zhong J, Wickramasinghe RS, Li X, Wu Y, Samuels I, Cherosky N,
Karlo JC, O’Loughlin B, Wikenheiser J, Gargesha M, Doughman YQ, Charron
J, Ginty DD, Watanabe M, Saitta SC, Snider WD, Landreth GE: Mouse and
human phenotypes indicate a critical conserved role for ERK2
signaling in neural crest development. Proc Natl Acad Sci USA 2008,
105(44):17115–17120.
27. Verhagen JM, Diderich KE, Oudesluijs G, Mancini GM, Eggink AJ, Verkleij-Hagoort
AC, Groenenberg IA, Willems PJ, du Plessis FA, de Man SA, Srebniak MI, van
Opstal D, Hulsman LO, van Zutven LJ, Wessels MW: Phenotypic variability
of atypical 22q11.2 deletions not including TBX1. Am J Med Genet 2012,
158A(10):2412–2420.
28. Breckpot J, Thienpont B, Bauters M, Tranchevent LC, Gewillig M, Allegaert K,
Vermeesch JR, Moreau Y, Devriendt K: Congenital heart defects in a novel
recurrent 22q11.2 deletion harboring the genes CRKL and MAPK1. Am J
Med Genet 2012, 158A(3):574–580.
29. Ogilvie CM, Ahn JW, Mann K, Roberts RG, Flinter F: A novel deletion in
proximal 22q associated with cardiac septal defects and microcephaly:
a case report. Mol Cytogenet 2009, 2:9.
30. D’Angelo CS, Jehee FS, Koiffmann CP: An inherited atypical 1 Mb 22q11.2
deletion within the DGS/VCFS 3 Mb region in a child with obesity and
aggressive behavior. Am J Med Genet 2007, 143A(16):1928–1932.
31. Mikhail FM, Descartes M, Piotrowski A, Andersson R, de Diaz Stahl T,
Komorowski J, Bruder CE, Dumanski JP, Carroll AJ: A previously
unrecognized microdeletion syndrome on chromosome 22 band q11.2
encompassing the BCR gene. Am J Med Genet 2007, 143A(18):2178–2184.
32. Fernandez L, Nevado J, Santos F, Heine-Suner D, Martinez-Glez V, Garcia-Minaur S,
Palomo R, Delicado A, Pajares IL, Palomares M, Garcia-Guereta L, Valverde
E, Hawkins F, Lapunzina P: A deletion and a duplication in distal 22q11.2
deletion syndrome region. Clinical implications and review. BMC Med
Genet 2009, 10:48.
33. Garavelli L, Rosato S, Wischmeijer A, Gelmini C, Esposito A, Mazzanti L,
Franchi F, De Crescenzo A, Palumbo O, Carella M, Riccio A: 22q11.2 Distal
Deletion Syndrome: Description of a New Case with Truncus Arteriosus
Type 2 and Review. Mol Syndromol 2011, 2(1):35–44.
34. Vorstman JA, Jalali GR, Rappaport EF, Hacker AM, Scott C, Emanuel BS:
MLPA: a rapid, reliable, and sensitive method for detection and analysis
of abnormalities of 22q. Human Mutat 2006, 27(8):814–821.35. Weksberg R, Hughes S, Moldovan L, Bassett AS, Chow EW, Squire JA:
A method for accurate detection of genomic microdeletions using
real-time quantitative PCR. BMC Genomics 2005, 6:180.
36. Mantripragada KK, Tapia-Paez I, Blennow E, Nilsson P, Wedell A, Dumanski
JP: DNA copy-number analysis of the 22q11 deletion-syndrome region
using array-CGH with genomic and PCR-based targets. Int J Mol Med
2004, 13(2):273–279.
37. Miller KA: FISH Diagnosis of 22q11.2 Deletion Syndrome. Newborn Infant
Nurs Rev 2008, 8(1):e11–e19.
38. Jalali GR, Vorstman JA, Errami A, Vijzelaar R, Biegel J, Shaikh T, Emanuel BS:
Detailed analysis of 22q11.2 with a high density MLPA probe set. Hum
Mutat 2008, 29(3):433–440.
39. Bittel DC, Yu S, Newkirk H, Kibiryeva N, Holt A 3rd, Butler MG, Cooley LD:
Refining the 22q11.2 deletion breakpoints in DiGeorge syndrome by
aCGH. Cytogen Genome Res 2009, 124(2):113–120.
40. Coffa J, van de Wiel MA, Diosdado B, Carvalho B, Schouten J, Meijer GA:
MLPAnalyzer: data analysis tool for reliable automated normalization of
MLPA fragment data. Cell Oncol 2008, 30(4):323–335.
41. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G:
Relative quantification of 40 nucleic acid sequences by multiplex
ligation-dependent probe amplification. Nucleic Acids Res 2002, 30(12):e57.
42. Frigerio M, Passeri E, de Filippis T, Rusconi D, Valaperta R, Carminati M,
Donnangelo A, Costa E, Persani L, Finelli P, Corbetta S: SNPs and real-time
quantitative PCR method for constitutional allelic copy number
determination, the VPREB1 marker case. BMC Med Genet 2011, 12:61.
43. Schwab CJ, Jones LR, Morrison H, Ryan SL, Yigittop H, Schouten JP, Harrison
CJ: Evaluation of multiplex ligation-dependent probe amplification as
a method for the detection of copy number abnormalities in B-cell
precursor acute lymphoblastic leukemia. Genes Chromosomes Cancer 2010,
49(12):1104–1113.
44. Hindson BJ, Ness KD, Masquelier DA, Belgrader P, Heredia NJ, Makarewicz
AJ, Bright IJ, Lucero MY, Hiddessen AL, Legler TC, Kitano TK, Hodel MR,
Petersen JF, Wyatt PW, Steenblock ER, Shah PH, Bousse LJ, Troup CB, Mellen
JC, Wittmann DK, Erndt NG, Cauley TH, Koehler RT, So AP, Dube S, Rose KA,
Montesclaros L, Wang S, Stumbo DP, Hodges SP, et al.: High-throughput
droplet digital PCR system for absolute quantitation of DNA copy
number. Anal Chem 2011, 83(22):8604–8610.
45. Pinheiro LB, Coleman VA, Hindson CM, Herrmann J, Hindson BJ, Bhat S,
Emslie KR: Evaluation of a droplet digital polymerase chain reaction
format for DNA copy number quantification. Anal Chem 2012,
84(2):1003–1011.
46. Wechsler D: Wechsler intelligence scale for children–Fourth Edition (WISC-IV).
San Antonio, TX: The Psychological Corporation; 2003.
47. Swanson J: SNAP-IV Scale. Irvine, Calif: University of California Child
Development Center; 1994.
48. Wechsler D: Wechsler abbreviated scale of intelligence. San Antonio, TX:
Psychological Corporation; 1999.
49. Lindsay EA, Botta A, Jurecic V, Carattini-Rivera S, Cheah YC, Rosenblatt HM,
Bradley A, Baldini A: Congenital heart disease in mice deficient for the
DiGeorge syndrome region. Nature 1999, 401(6751):379–383.
50. Gong W, Gottlieb S, Collins J, Blescia A, Dietz H, Goldmuntz E, McDonald-McGinn
DM, Zackai EH, Emanuel BS, Driscoll DA, Budarf ML: Mutation analysis of TBX1
in non-deleted patients with features of DGS/VCFS or isolated cardiovascular
defects. J Med Genet 2001, 38(12):E45.
51. Conti E, Grifone N, Sarkozy A, Tandoi C, Marino B, Digilio MC, Mingarelli R,
Pizzuti A, Dallapiccola B: DiGeorge subtypes of nonsyndromic conotruncal
defects: evidence against a major role of TBX1 gene. Eur J Hum Genet
2003, 11(4):349–351.
52. Ambros V: microRNAs: tiny regulators with great potential. Cell 2001,
107(7):823–826.
53. Denli AM, Tops BB, Plasterk RH, Ketting RF, Hannon GJ: Processing of
primary microRNAs by the Microprocessor complex. Nature 2004,
432(7014):231–235.
54. Gregory RI, Yan KP, Amuthan G, Chendrimada T, Doratotaj B, Cooch N,
Shiekhattar R: The Microprocessor complex mediates the genesis of
microRNAs. Nature 2004, 432(7014):235–240.
55. Han J, Lee Y, Yeom KH, Nam JW, Heo I, Rhee JK, Sohn SY, Cho Y, Zhang BT,
Kim VN: Molecular basis for the recognition of primary microRNAs by the
Drosha-DGCR8 complex. Cell 2006, 125(5):887–901.
56. Lai EC: microRNAs: runts of the genome assert themselves. Current Biol
2003, 13(23):R925–R936.
Hwang et al. BMC Medical Genetics 2014, 15:106 Page 12 of 12
http://www.biomedcentral.com/1471-2350/15/10657. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Radmark O, Kim
S, Kim VN: The nuclear RNase III Drosha initiates microRNA processing.
Nature 2003, 425(6956):415–419.
58. Han J, Lee Y, Yeom KH, Kim YK, Jin H, Kim VN: The Drosha-DGCR8 complex
in primary microRNA processing. Genes Dev 2004, 18(24):3016–3027.
59. Wang Y, Medvid R, Melton C, Jaenisch R, Blelloch R: DGCR8 is essential for
microRNA biogenesis and silencing of embryonic stem cell self-renewal.
Nat Genet 2007, 39(3):380–385.
60. Rao PK, Toyama Y, Chiang HR, Gupta S, Bauer M, Medvid R, Reinhardt F,
Liao R, Krieger M, Jaenisch R, Lodish HF, Blelloch R: Loss of cardiac
microRNA-mediated regulation leads to dilated cardiomyopathy and
heart failure. Circ Res 2009, 105(6):585–594.
61. Huang ZP, Chen JF, Regan JN, Maguire CT, Tang RH, Dong XR, Majesky MW,
Wang DZ: Loss of microRNAs in neural crest leads to cardiovascular
syndromes resembling human congenital heart defects. Arterioscler
Thromb Vasc Biol 2010, 30(12):2575–2586.
62. de la Morena MT, Eitson JL, Dozmorov IM, Belkaya S, Hoover AR, Anguiano
E, Pascual MV, van Oers NS: Signature MicroRNA expression patterns
identified in humans with 22q11.2 deletion/DiGeorge syndrome. Clin
Immunol 2013, 147(1):11–22.
doi:10.1186/s12881-014-0106-5
Cite this article as: Hwang et al.: Mapping the deletion endpoints in
individuals with 22q11.2 Deletion Syndrome by droplet digital PCR. BMC
Medical Genetics 2014 15:106.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
